West Pharmaceutical Services (WST) Projected to Post Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is anticipated to release its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect the company to post earnings of $2.08 per share and revenue of $839.9790 million for the quarter. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:00 AM ET.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.45. The company had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.45 earnings per share. On average, analysts expect West Pharmaceutical Services to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

West Pharmaceutical Services Stock Up 0.3%

WST stock opened at $358.79 on Thursday. The stock has a 50-day simple moving average of $331.26 and a two-hundred day simple moving average of $283.67. The firm has a market capitalization of $25.35 billion, a PE ratio of 47.97, a PEG ratio of 2.99 and a beta of 1.16. West Pharmaceutical Services has a twelve month low of $206.80 and a twelve month high of $367.66. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday. KeyCorp upped their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Finally, Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $363.17.

Insider Transactions at West Pharmaceutical Services

In related news, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer directly owned 1,523 shares in the company, valued at approximately $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by insiders.

Hedge Funds Weigh In On West Pharmaceutical Services

Institutional investors and hedge funds have recently made changes to their positions in the business. CYBER HORNET ETFs LLC bought a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth approximately $25,000. DV Equities LLC bought a new position in West Pharmaceutical Services in the 4th quarter worth about $28,000. MUFG Securities EMEA plc purchased a new stake in West Pharmaceutical Services during the 2nd quarter valued at about $47,000. State of Wyoming purchased a new stake in West Pharmaceutical Services during the 2nd quarter valued at about $49,000. Finally, Meeder Asset Management Inc. increased its position in shares of West Pharmaceutical Services by 1,023.5% during the fourth quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 174 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.